Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atossa Therapeutics Inc (NQ: ATOS )

1.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.510
Bid (Size) 1.450 (5)
Ask (Size) 1.740 (10)
Prev. Close 1.510
Today's Range 1.510 - 1.510
52wk Range 0.6000 - 2.310
Shares Outstanding 125,785,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MicroMarvel - Atossa Therapeutics
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals 
Via Talk Markets
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+61.50%
+61.50%
1 Month
-24.50%
-24.50%
3 Month
+77.23%
+77.23%
6 Month
+125.24%
+125.24%
1 Year
+151.67%
+151.67%

More News

Read More
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
Via InvestorPlace
This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm"
Via Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via ACCESSWIRE
Atossa Therapeutics backing Endoxifen in the fight against breast cancer
Via News Direct
Recap: Atossa Therapeutics Q2 Earnings
Via Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
Via ACCESSWIRE
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
Via Benzinga
3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True
Via InvestorPlace
3 Penny Stocks Set to Pass the $5 Mark Soon
Via InvestorPlace
3 Penny Stocks That Could Skyrocket in the Next 12 Months
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Via InvestorPlace
3 Best Penny Stocks Under $1 to Buy in April
Via InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for April
Via InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.